IFNG and cancer: To investigate the role of IFNγ in PD-L1 upregulation, we first incubated cancer cells without or with CD64-CR T cells in the presence or absence of a scalar dose of the JAK2 inhibitor ruxolitinib, which inhibited the upregulation of PD-L1 in a dose-response manner (Fig. 7C).